Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Preoperative Window of Opportunity Study With Giredestrant (GDC-9545) or Tamoxifen in Premenopausal Women With Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative & Ki67≥10% Early Breast Cancer

NCT05659563 is registered in ClinicalTrials.gov with MedSIR as lead sponsor.

NCT NCT05659563
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05659563 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Preoperative Window of Opportunity Study With Giredestrant (GDC-9545) or Tamoxifen in Premenopausal Women With Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative & Ki67≥10% Early Breast Cancer
Lead sponsor
MedSIR
Phase
Phase 2
Overall status
Completed
Start date
July 20, 2023
Completion date
January 30, 2025
Enrollment
92 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, breast cancer, early-onset